JUBLPHARMA
530019Receipt Of Show Cause Notice By Jubilant Pharmova Limited - GST
Receipt of Show Cause Notice by Jubilant Pharmova Limited - GST
Jubilant Pharmova Ltd is an integrated global pharmaceutical and life sciences company headquartered in Noida, India. The company operates through subsidiaries and business segments that encompass pharmaceuticals, contract research and development, and specialty pharmaceutical ingredients. Jubilant Pharmova provides a wide range of products and services including generics, specialty pharmaceuticals, and radiopharmaceuticals, serving regulated markets such as the United States, Europe, and other international geographies.
Receipt Of Show Cause Notice By Jubilant Pharmova Limited - GST
Receipt of Show Cause Notice by Jubilant Pharmova Limited - GST
Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Publication - Relodgement and KYC Updation
Receipt Of Show Cause Notice - Jubilant Generics Limited
Receipt of Show Cause Notice - Jubilant Generics Limited
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Scrutinizer''s Report
Shareholder Meeting / Postal Ballot-Outcome of AGM
Outcome of AGM
USFDA Approval For Line 3, Contract Manufacturing Facility, Spokane, U.S.A
USFDA Approval for Line 3, Contract manufacturing facility, Spokane, USA
Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot
Outcome of Postal Ballot
Shareholder Meeting / Postal Ballot-Scrutinizer"s Report
Scrutinizer''s Report
Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Publications
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release and presentation
Un-Audited Standalone & Consolidated Financial Results For The Quarter Ended June 30, 2026
Un-audited Financial Results for the Quarter ended June 30, 2026
Board Meeting Outcome for Meeting Held On August 10, 2026
outcome of Board meeting
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Investors/ Analysts Meeting
Board Meeting Intimation for Postponement And Rescheduling Of Board Meeting Scheduled For August 10, 2026
Jubilant Pharmova Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2026 ,inter alia, to consider and approve the Un-audited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2026
Newspaper Advertisements Titled ''Notice Of 48Th Annual General Meeting, E-Voting, Record Date And Final Dividend Information
Newspaper advertisements titled ''Notice of 48th Annual General Meeting, E-voting, Record Date and Final Dividend Information''
Jubilant Pharmova Ltd
About
Jubilant Pharmova Ltd is an integrated global pharmaceutical and life sciences company headquartered in Noida, India. The company operates through subsidiaries and business segments that encompass pharmaceuticals, contract research and development, and specialty pharmaceutical ingredients. Jubilant Pharmova provides a wide range of products and services including generics, specialty pharmaceuticals, and radiopharmaceuticals, serving regulated markets such as the United States, Europe, and other international geographies.
Jubilant Pharmova’s business is structured to address multiple segments of the healthcare industry, from proprietary products to contract research, manufacturing, and drug discovery. The company maintains US FDA-approved manufacturing facilities and R&D centers, leveraging its research-driven approach and global supply chain to deliver quality and compliance for its clients and partners worldwide.
Business Model & Strategy
Jubilant Pharmova generates revenue primarily from the manufacture and sale of pharmaceuticals, specialty pharmaceuticals, and life science ingredients to regulated and emerging markets. Its core business units include: Pharmaceuticals (generics, contract manufacturing, contract research, radiopharmaceuticals) and Drug Discovery Solutions (providing integrated and standalone drug discovery and development services to global biotech and pharmaceutical companies).
The company’s strategic focus lies in expanding its radiopharma portfolio, strengthening R&D investments, and growing its contract development and manufacturing organization (CDMO) and contract research businesses. Diversification across therapeutic areas and geographies, recurring long-term contracts, and investments in compliance and capacity expansion underpin its growth strategy. Incremental investments in digital transformation and sustainability initiatives are also a focus for operational optimization.
Management Overview
12 MembersMr.Shyam Sunder Bhartia
Non-Executive - Non Independent Director-Chairperson related to PromoterMr.Hari Shanker Bhartia
Non-Executive - Non Independent DirectorMr.Sushil Kumar Roongta
Non-Executive - Independent DirectorMr.Vivek Mehra
Non-Executive - Independent DirectorMr.Arun Seth
Non-Executive - Independent DirectorMr.Shirish Gundopant Belapure
Non-Executive - Independent DirectorMr.Priyavrat Bhartia
Executive Director-MDMr.Arjun Shanker Bhartia
Executive Director-MDMr.Arvind Chokhany
Executive DirectorMs.Shivpriya Nanda
Non-Executive - Independent DirectorMr.Harsh Mahajan
Non-Executive - Independent DirectorMr.Naresh Kapoor
Company Secretary & Compliance OfficerAwards & Recognition
4 Awards- 2024: Included in the FTSE4Good Index for ESG practices
- 2024: Recognized as a 'Top 50 India Innovative Pharma Companies' by Biospectrum India
- 2023: Received CMO Leadership Award in Reliability (Life Science Leader Magazine)
- 2023: Awarded Great Place to Work® Certification (India)
Market Information
Company Timeline
46+ Years of Excellence | 7 Major Milestones
Company founded as Vam Organic Chemicals Ltd
Listed on the BSE
Entered drug discovery and life sciences business
Rebranded as Jubilant Life Sciences Ltd
Demerger of Life Science Ingredients business; rebranded as Jubilant Pharmova Ltd
Strengthened radiopharma capabilities with new plant and acquisitions in North America
Expanded CDMO operations and signed new long-term global contracts
The Next Evolution
Contact Information
Registered Office
Bhartiagram, Gajraula, Jyotiba Phoolay Nagar
Tel: 0120-4361000,
Fax: 0120-4264895 / 96,
Email: investors@jubl.com
Website: jubilantpharmova.com
Corporate Actions
13| Purpose | Ex Date | Record Date | BC Start | BC End |
|---|---|---|---|---|
Final Dividend ₹5 per share | 24 Jul 2026 Friday | 24 Jul 2026 Friday | - | - |
Final Dividend ₹5 per share | 25 Jul 2025 Friday | 25 Jul 2025 Friday | - | - |
Final Dividend ₹5 per share | 02 Aug 2024 Friday | 02 Aug 2024 Friday | - | - |
Final Dividend ₹5 per share | 10 Aug 2023 Thursday | 10 Aug 2023 Thursday | - | - |
Final Dividend ₹5 per share | 11 Aug 2022 Thursday | 12 Aug 2022 Friday | - | - |
Final Dividend ₹5 per share | 05 Aug 2021 Thursday | 06 Aug 2021 Friday | - | - |
Spin Off | 04 Feb 2021 Thursday | 05 Feb 2021 Friday | - | - |
Interim Dividend ₹5 per share | 09 Mar 2020 Monday | 11 Mar 2020 Wednesday | - | - |
Final Dividend ₹4.50 per share | 12 Sep 2019 Thursday | - | 14 Sep 2019 Saturday | 25 Sep 2019 Wednesday |
Dividend ₹3 per share | 12 Sep 2018 Wednesday | - | 15 Sep 2018 Saturday | 26 Sep 2018 Wednesday |
Dividend ₹3 per share | 16 Aug 2017 Wednesday | - | 19 Aug 2017 Saturday | 29 Aug 2017 Tuesday |
Dividend ₹3 per share | 18 Aug 2016 Thursday | - | 20 Aug 2016 Saturday | 30 Aug 2016 Tuesday |
Dividend ₹3 per share | 20 Aug 2015 Thursday | - | 22 Aug 2015 Saturday | 01 Sep 2015 Tuesday |
₹14,335 Cr.
₹904
₹1,185 / 786
40.51
₹445.48
2.02
₹22.23
₹1.00
0.56 %
Manage Ratio
FINANCIALS
| Annual Results | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income | - | - | - | 9,147 | 9,202 | 6,116 | 6,141 | 6,320 | 677 | 7,291 | 8,346 | 8,682 |
| Expenses | - | - | - | 7,963 | 7,957 | 5,235 | 5,501 | 6,248 | 646 | 6,670 | 7,672 | 8,077 |
| Profit | - | - | - | 577 | 898 | 836 | 413 | -64.88 | 7 | 836 | 398 | 351 |
| Tax | - | - | - | 327 | 312 | 297 | 217 | 93 | 10 | 144 | 217 | 195 |
| EPS | - | - | - | 37 | 56 | 36 | 26 | -3.83 | 5 | 53 | 25 | 3.57 |
| Ratios | - |
Cash Flow
Consolidated Figures in Rs. Crores
| Annual Balance Sheet | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | - |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | - | - | - | 11,469 | 12,522 | 8,918 | 9,991 | 11,157 | 1,155 | 12,756 | 15,523 | - |
| Equity And Liabilities | - | - | - | 11,469 | 12,522 | 8,918 | 9,991 | 11,157 | 1,155 | 12,756 | 15,523 | - |
Shareholding Pattern
Numbers in Percentages
| Quarterly SHP Announcement Date | Mar 2016 12 Apr '16 | Mar 2017 31 Mar '17 | Mar 2018 31 Mar '18 | Mar 2019 19 Apr '19 | Mar 2020 20 Apr '20 | Mar 2021 20 Apr '21 | Mar 2022 18 Apr '22 | Mar 2023 24 May '23 | Mar 2024 19 Apr '24 | Mar 2025 17 Apr '25 | Mar 2026 18 Apr '26 | - |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Goverments | - | - | - | - | - | - | - | 1.24% | - | - | - | - |
| Promoter And Promoter Group | - | - | - | 50.68% | 50.68% | 50.68% | 50.68% | 50.68% | 50.68% | 50.68% | 47.68% | - |
| Non Institutions | - | - | - | 17.80% | 19.54% | 22.29% | 25.18% | 23.10% | 25.90% | 24.50% | 24.24% | - |
| FII | - | - | - | - | - | - | - | 23.22% | 19.06% | 17.22% | 15.90% | - |
| DII | - | - | - | - | - | - | - | 1.63% | 3.78% | 7.05% | 11.62% | - |
| Total | - | - | - | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | - |
Jubilant Pharmova Ltd
Jubilant Pharmova Ltd
Jubilant Pharmova Ltd is an integrated global pharmaceutical and life sciences company headquartered in Noida, India. The company operates through subsidiaries and business segments that encompass pharmaceuticals, contract research and development, and specialty pharmaceutical ingredients. Jubilant Pharmova provides a wide range of products and services including generics, specialty pharmaceuticals, and radiopharmaceuticals, serving regulated markets such as the United States, Europe, and other international geographies.
Jubilant Pharmova’s business is structured to address multiple segments of the healthcare industry, from proprietary products to contract research, manufacturing, and drug discovery. The company maintains US FDA-approved manufacturing facilities and R&D centers, leveraging its research-driven approach and global supply chain to deliver quality and compliance for its clients and partners worldwide.
Jubilant Pharmova generates revenue primarily from the manufacture and sale of pharmaceuticals, specialty pharmaceuticals, and life science ingredients to regulated and emerging markets. Its core business units include: Pharmaceuticals (generics, contract manufacturing, contract research, radiopharmaceuticals) and Drug Discovery Solutions (providing integrated and standalone drug discovery and development services to global biotech and pharmaceutical companies).
The company’s strategic focus lies in expanding its radiopharma portfolio, strengthening R&D investments, and growing its contract development and manufacturing organization (CDMO) and contract research businesses. Diversification across therapeutic areas and geographies, recurring long-term contracts, and investments in compliance and capacity expansion underpin its growth strategy. Incremental investments in digital transformation and sustainability initiatives are also a focus for operational optimization.
2024: Included in the FTSE4Good Index for ESG practices
2024: Recognized as a 'Top 50 India Innovative Pharma Companies' by Biospectrum India
2023: Received CMO Leadership Award in Reliability (Life Science Leader Magazine)
2023: Awarded Great Place to Work® Certification (India)
Company founded as Vam Organic Chemicals Ltd
Listed on the BSE
Entered drug discovery and life sciences business
Rebranded as Jubilant Life Sciences Ltd
Demerger of Life Science Ingredients business; rebranded as Jubilant Pharmova Ltd
Strengthened radiopharma capabilities with new plant and acquisitions in North America
Expanded CDMO operations and signed new long-term global contracts
Peer Comparison
| S.No. | Company Name | CMP (₹) | Market Cap (₹ Cr) | Div Yld (%) | NP Qtr (₹ Cr) | Qtr Profit Var (%) | Sales Qtr (₹ Cr) | Qtr Sales Var (%) | ROCE (%) | ROE (%) | Book Value (₹) | EPS TTM (₹) | TTMPE Ratio (₹) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Not Found Data | |||||||||||||
Coming Soon
Heatmap View
Premium Feature| Company | CMP (₹) | MCap (₹ Cr) | EPS TTM (₹) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Not Found Data | |||||||||||||
Financial Ratios
Premium Feature| Company Name | P/E (TTM) | EPS (₹) | D/E | NPM | GPM | ROE (%) | ROCE (%) | P/B | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Not Found Data | |||||||||||||
Coming Soon